Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Want to see AMRN full AI Analyst Report?
AMRN Stock Chart & Stats
$14.98
-$0.01(-2.55%)
At close: 4:00 PM EST
$14.98
-$0.01(-2.55%)
Day’s Range― - ―
52-Week Range$12.30 - $20.90
Previous CloseN/A
Volume726.09K
Average Volume (3M)81.56K
Market Cap
$336.31M
Enterprise Value$200.69M
Total Cash (Recent Filing)$307.82M
Total Debt (Recent Filing)$5.58M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding20,969,109
10 Day Avg. Volume89,987
30 Day Avg. Volume81,558
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit1.78
Enterprise Value/Ebitda-39.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)$174.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe total revenues included a $25M upfront payment from the Recordati deal, contributing to the overall revenue growth.
Strategic PartnershipsThe Recordati partnership in Europe helps reshape Amarin's business model by transferring commercialization to a seasoned local partner with established cardiovascular infrastructure and expertise.
Bears Say
Competition ChallengesThe longer-term outlook for the US Vascepa business remains conservative given growing pressure from generic competitors.
Market CompetitionInvestors may remain cautious about the commercial business as the US VASCEPA franchise continues to face significant pressure from at least eight generic competitors.
Amarin News
AMRN FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was $12.30 and its highest was $20.90 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is $336.31M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Aug 05, 2026 which is in 44 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Apr 29, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of $0.01 by -$0.04.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -0.02.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 20,969,109 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of -$0.03 in its last earnings report, missing expectations of $0.01. Following the earnings report the stock price went up 2.364%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in AMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amarin Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AMRN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 112.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.76%
12-Months-Change
Fundamentals
Return on Equity
-7.34%
Trailing 12-Months
Asset Growth
-1.51%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
AMRN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational progress: revenue growth, meaningful expense reductions, improved operating losses, second consecutive quarter of positive operating cash flow, a strong cash position with no debt, and accelerating international traction via the Recordati partnership. Offsetting risks include materially higher COGS in the near term (62% YoY increase), quarter-to-quarter revenue variability from the partnered model, ongoing U.S. generic competition risk, and remaining restructuring charges. On balance, the positive developments (cash generation, cost savings, market-share gains, favorable guideline positioning, and international rollout momentum) outweigh the near-term headwinds.View all AMRN earnings summariesTechnical Analysis
Altimmune
―
Rigel
―
Aldeyra Therapeutics
―
Rocket Pharmaceuticals
―
Corvus Pharmaceuticals
―
Ownership Overview
0.73% Insiders
1.80% Mutual Funds
12.36% Other Institutional Investors
85.00% Public Companies and
Individual Investors